Why the study?
Do new platinum complexes improve survival in Wistar rats with benzo(a)pyrene-induced tumours?
Do new platinum complexes improve survival in Wistar rats with benzo(a)pyrene-induced tumours?
Two new platinum complexes demonstrated effective antitumour activity by prolonging survival in a rat tumour model, with reversible toxicities.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for platinum complexes in rat tumor models; human trials required before clinical translation.
BACKGROUND: Cancer chemotherapy in humans based on metal complexes started at the clinical level in the late 1970s with the use of cisplatin, which forms intra-strand cross-links with DNA. METHODS: Two new platinum complexes of cis-geometry with the amino acids inosine (ino) and l-alanine (ala), Pt(ino)2Cl2 and cis-[Pt(NH3)2(ala)](NO3), respectively, were synthesized and pure samples were obtained by means of flash chromatography. These complexes were tested on benzo(a)pyrene-induced tumours in Wistar rats to detect their antitumour and toxic effects. RESULTS: There was a statistically significant prolongation of the mean survival time of the animals in the two groups tested (272 +/- 18 days and 246 +/- 26 days, respectively) compared to the control group (195 +/- 22 days) (P < 0.001). Toxic effects included a decrease in leucocyte cell count, mild haemolysis, mild haematuria, mild hepatotoxicity, elevated body temperature and hair loss. All of these effects were reversible after drug discontinuation. CONCLUSIONS: The two new platinum complexes described here appear to have an effective antitumour activity without severe toxicity when tested on Wistar rats.
No takes yet. Share an insight, caveat, or question.
Charalabopoulos et al. (2002) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: